Effects of Oxytocin on Bleeding Outcomes During Dilation and Evacuation

Status:	Completed
Healthy:	No
Age Range:	14 - 50
Updated:	5/17/2018
Start Date:	October 2014
End Date:	February 2018

A Randomized Double-blinded Controlled Trial Comparing Dilation and Evacuation Outcomes With and Without Oxytocin Use

Currently, there is very little research to identify ways to decrease blood loss during D&E
(dilation and evacuation) procedures. The objective is to determine whether routine use of
intravenous oxytocin will improve bleeding outcomes at the time of D&E at 18-24-weeks
gestation. To evaluate the hypothesis, investigators will perform a randomized,
double-blinded, placebo-controlled trial. The patient will be followed until discharged from
the postoperative care unit during which time patient satisfaction, pain score and
postoperative bleeding will be assessed.

Inclusion Criteria:

- Requesting pregnancy termination

- Intrauterine pregnancy at 18- to 24-weeks gestation

- Gestational-age to be confirmed by ultrasound

- Patients with fetal anomaly or intrauterine fetal demise that occurred at 18- to
24-weeks gestation

- Willing and able to understand and sign written informed consents in English or
Spanish and comply with study procedures

Exclusion Criteria:

- Ultrasound findings suggestive of placenta accreta

- Patients requiring preoperative misoprostol

We found this trial at

sites

Univ of Washington

Seattle, Washington 98104

(206) 543-2100